Latest News and Press Releases
Want to stay updated on the latest news?
-
resTORbio to Present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019
BOSTON, Aug. 07, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
-
– Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020 – – PROTECTOR 2 is planned to start in the fourth quarter of 2019, with topline data expected in mid-2020 – ...
-
RTB101 10 mg once daily was observed to reduce the rate of laboratory-confirmed Respiratory Tract Infections (RTIs) by 78.7% (p=0.001) and the rate of all RTIs (with or without laboratory...
-
Initiated first Phase 3 trial, PROTECTOR 1, of RTB101 in clinically symptomatic respiratory illness; top-line data from two pivotal Phase 3 trials expected in mid-2020 Initiated Phase 1b/2a trial of...
-
BOSTON, May 14, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
-
BOSTON, May 13, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that it will present additional results from the Phase 2b trial evaluating RTB101 (dactolisib), an oral,...
-
BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small molecule,...
-
BOSTON, May 01, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
-
BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
-
BOSTON, March 22, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the...